Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
Gene editor shelves sole clinical asset, lays off 25% of staff
Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine.
Gabrielle Masson
May 19, 2025 2:28pm
ADC Therapeutics calls time on sole clinical-stage candidate
May 14, 2025 9:55am
Arcturus doubles down on mRNA, axes several early-stage assets
May 13, 2025 1:32pm
Tango dances away from preclinical work to extend cash runway
May 12, 2025 8:37am
NGM Bio cuts 75% of staff, halts midstage liver disease program
May 12, 2025 7:00am
Takeda shoots down bispecifics bagged in Maverick buyout
May 8, 2025 8:30am
